CLASS III Drug recall · Reported 22 Aug 2012 · FDA Enforcement Report

Carboplatin Injection, 10 mg/mL, a) multi-dose vials recalled by Hospira

Hospira is recalling Carboplatin Injection, 10 mg/mL, a) multi-dose vials (, distributed nationwide in the US. The recall was initiated on 2 Jul 2012 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codes5 mL vial - NDC 61703-339-18 (Hospira label), lot number Y031654AB, expiration APR2013; NDC 61703-360-18 (Novoplus label), lot number Y031654AA, expiration APR2013; 45 mL vial - NDC 61703-339-50 (Hospira label), lot numbers Y041711AA, expiration DEC 2012 and Y061711AB, expiration FEB 2013; NDC 61703-360-50 (Novoplus label), lot number Y061711AA, expiration FEB 2013
NDC61703-339, 61703-150, 61703-360, 61703-262, 61703-600
Quantity recalled77,542 vials

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1648-2012
FDA event ID
62463
Recalling firm
Hospira, Lake Forest, IL
Manufacturer
Hospira, Inc.
Classification
Class III
Status
Terminated
Recall initiated
2 Jul 2012
FDA classified
16 Aug 2012
Reported
22 Aug 2012
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

2 Jul 2012Recall initiated by company
16 Aug 2012Classified by FDA+45 days
22 Aug 2012Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed PH specification: The lots of Carboplatin Injection were manufactured from Carboplatin API lots which trended out of specification low pH.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Carboplatin Injection, 10 mg/mL, a) 5 mL multi-dose vials (NDC 61703-339-18) (NDC 61703-360-18, NOVAPLUS), b) 45 mL multi-dose vials (NDC 61703-339-50) (NDC 61703-360-50 NOVAPLUS), Rx only, Hospira, Inc., Lake Forest, IL 60045, Product of Australia

Where it was distributed

Nationwide and Puerto Rico

Nationwide Puerto Rico

Questions about this recall

Is Carboplatin Injection, 10 mg/mL, a) multi-dose vials ( recalled?

Yes. Hospira recalled Carboplatin Injection, 10 mg/mL, a) multi-dose vials ( on 2 Jul 2012. The recall is Class III and its status is Terminated. Recall number D-1648-2012.

Why was it recalled?

Failed PH specification: The lots of Carboplatin Injection were manufactured from Carboplatin API lots which trended out of specification low pH.

Which lots are affected?

5 mL vial - NDC 61703-339-18 (Hospira label), lot number Y031654AB, expiration APR2013; NDC 61703-360-18 (Novoplus label), lot number Y031654AA, expiration APR2013; 45 mL vial - NDC 61703-339-50 (Hospira label), lot numbers Y041711AA, expiration DEC 2012 and Y061711AB, expiration FEB 2013; NDC 61703-360-50 (Novoplus label), lot number Y061711AA, expiration FEB 2013

Where was it sold?

Nationwide and Puerto Rico

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Hospira

All 225

Other Carboplatin recalls

All 6